Osteosarcoma (OS) has been described as the most common primary malignant bone tumor in adolescents and young adults worldwide. MicroRNAs (miRNAs) have demonstrated playing critical role on the cellular biology and development of cancer. However, the essential mechanisms of miRNAs underlying osteosarcoma oncogenesis and progression have not fully understood. In this study, we found that the expression of miR-99a was repressed in OS tissues and cells using qRT-PCR assays. We demonstrated that overexpression of miR-99a inhibits OS cell viability and growth with MTT, colony formation and in vivo mice experiment. In addition, FACS and Annexin V assays identified that miR-99a can induce OS cell cycle progression and cell apoptosis. Furthermore, we demonstrated that TNFAIP8 is a direct target of miR-99a and is upregulated in OS samples and cells. Knockdown of TNFAIP8 significantly attenuated OS cell viability and growth through inhibiting cell cycle and inducing cell apoptosis in vitro and in vivo. These findings establish that miR-99a plays a significant tumor-suppressing role in OS and proposes it as a potential diagnostic and therapeutic target in managing OS metastases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846951 | PMC |
Int J Mol Sci
November 2024
School of Public Health, North China University of Science and Technology, Tangshan 063210, China.
Silicosis is one of the most prevalent and fatal occupational diseases worldwide, with unsatisfactory clinical outcomes. This study aimed to investigate the therapeutic effect and related molecular mechanisms of how mesenchymal stem cell (MSC)-secreted exosomes alleviate SiO-induced pulmonary fibrosis. miR-99a-5p was significantly downregulated in silicosis models via high-throughput miRNA screening, and was overlapped with miRNAs in exosomes from MSCs.
View Article and Find Full Text PDFFront Genet
November 2024
Department of Cell and Molecular Biology, School of Life Science and Technology, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing, Jiangsu, China.
Immunotargets Ther
November 2024
Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266003, People's Republic of China.
Background: Sorafenib, an orally active potent tyrosine kinase inhibitor (TKI), represented a primary treatment in patients with advanced hepatocellular carcinoma (HCC). Unfortunately, sorafenib resistance was regarded as a huge obstacle for HCC treatment.
Methods: RNA-sequencing including circRNA Sequencing (circRNA-Seq) for circular RNAs (circRNAs), miRNA Sequencing (miRNA-Seq) for microRNAs (miRNAs), as well as mRNA Sequencing (mRNA-Seq) for mRNAs in , were performed.
Adv Sci (Weinh)
December 2024
MOE Key Laboratory of Tumor Molecular Biology and State Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
The mammalian target of rapamycin (mTOR) is a critical signaling hub for sustaining cancer survival. Targeting mTOR and inducing autophagic cell death downstream of it represent promising therapeutic strategies for cancer prevention. A US Food and Drug Administration-approved drug library containing 616 small molecules is used to screen anticancer drugs against colorectal cancer (CRC) cells that rely on mTOR.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!